These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22949142)

  • 21. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 24. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
    Zannad F; Gattis Stough W; Rossignol P; Bauersachs J; McMurray JJ; Swedberg K; Struthers AD; Voors AA; Ruilope LM; Bakris GL; O'Connor CM; Gheorghiade M; Mentz RJ; Cohen-Solal A; Maggioni AP; Beygui F; Filippatos GS; Massy ZA; Pathak A; Piña IL; Sabbah HN; Sica DA; Tavazzi L; Pitt B
    Eur Heart J; 2012 Nov; 33(22):2782-95. PubMed ID: 22942339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
    Pitt B; Rossignol P
    Expert Opin Drug Saf; 2016 May; 15(5):659-65. PubMed ID: 26958701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone receptor antagonists in the medical management of chronic heart failure.
    Tang WH; Parameswaran AC; Maroo AP; Francis GS
    Mayo Clin Proc; 2005 Dec; 80(12):1623-30. PubMed ID: 16342656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
    Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
    Int J Cardiol; 2013 Jul; 167(1):244-9. PubMed ID: 22245478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spironolactone in the treatment of congestive heart failure.
    Lloyd SJ; Mauro VF
    Ann Pharmacother; 2000 Nov; 34(11):1336-40. PubMed ID: 11098350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
    Coats AJ
    Int J Cardiol; 2001 Aug; 80(1):1-4. PubMed ID: 11532539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C; Castelli G; Crea F; Gavazzi A; Gensini GF; Scherillo M; Sinagra G
    G Ital Cardiol (Rome); 2012 Dec; 13(12):809-16. PubMed ID: 23196683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
    Heggermont WA; Goethals M; Dierckx R; Verstreken S; Bartunek J; Vanderheyden M
    Heart Fail Rev; 2016 Nov; 21(6):699-701. PubMed ID: 27620301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.